


Alphamab to strengthen global innovative platforms

20 November 2018 | News

The company focuses on the research and development of innovative biologics for cancer therapy.



Alphamab Oncology has announced the successful completion of series A financing round, with more than \$100 million raised. A number of well-regarded institutional investors, including Advantech Capital, PAG, China Venture Capital Fund, OrbiMed, Heritage Provider Network and Janchor Partners, participated in the financing.

Alphamab Oncology plans to use the proceeds to advance global clinical development of its innovative pipeline, especially its second-generation immuno-oncology medicine, to expand its global clinical and commercial teams, as well as to complete the ongoing construction of its state-of-the-art biologics manufacturing facilities.

Alphamab Oncology inherited Suzhou Alphamab's oncology pipeline and related technology platforms. The company focuses on the research and development of innovative biologics for cancer therapy, and it has developed several proprietary and robust technology platforms for bispecific and mixed antibodies. Leveraging on these world-leading protein engineering platforms, Alphamab Oncology is well positioned to develop next-generation multi-functional biologics therapy for cancer treatment.